Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
A surprisingly successful study of Opdivo and Yervoy suggests that the enrolment of so-called hyperprogressors could have scuppered other trials.
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.